For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Healing & Recovery

BPC-157 + TB-500

Also known as: Wolverine Blend

Pre-mixed blend of BPC-157 and TB-500 (a synthetic Thymosin β4 fragment) in a single vial, marketed for tissue repair. This blend is not clinically validated; the evidence base is inferred from individual component peptides, both of which are grey-market research compounds with no FDA-approved human indications and no controlled human efficacy trials.

Where to buy · live market data

Who's worth your money for BPC-157 + TB-500

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 27 scored sellers

$4.40/mg

$880 · 200mg · 99.6% purity

Best value

Lowest $/mg among scored sellers

$1.04/mg

$208 · 200mg

no COAs yet

Most tested

8 independent COAs on file

$5.35/mg

$107 · 20mg

Average price

$4.90/mg

Sellers

55

45-day trend

-2.3%

45 of 55 sellers have a current price· 10 stale hidden· 8 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch BPC-157 + TB-500

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About BPC-157 + TB-500

CAS

Molecular formula

Typical dose range

BPC-157: 250–500 mcg/day subcutaneous (1–2× daily); TB-500: 2–5 mg twice weekly subcutaneous (loading), 2 mg once weekly (maintenance)

Half-life

BPC-157: disputed (~4 hours per some sources, under 30 minutes per others, subcutaneous); TB-500: ~2 hours plasma half-life

Independent evidence

COAs for BPC-157 + TB-500

90 third-party tests across 28 vendors. Each card links to the full report.

All 90 COAs for BPC-157 + TB-500 →
Measured purity 97.4%–100.0% across 29 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.00 %
Jun 2026
Ethos Analytics Strong

For

ARA-290/BPC-157/TB-500

by OROS Research· batch OR-LPREGEN40-526-B2

Aggregated · 3rd-party listing
99.90 %
Jun 2026
ILS Labs Strong

For

Wolverine

by Crush Research· batch CR-BPTB20-2605-1

Aggregated · 3rd-party listing
99.95 %
May 2026
ILS Labs Strong

For

BPC+TB 20MG

by NG Peptide· batch BPTB-07

Aggregated · 3rd-party listing
99.31 %
May 2026
ILS Labs Strong

For

BPC+TB 5/5

by NG Peptide· batch BPTB10-4

Aggregated · 3rd-party listing
99.00 %
Apr 2026
Ethos Analytics Strong · HPLC

For

BPC-157 + TB-500

by OROS Research· batch OR-LPBPCTB10-426-B4

Aggregated · 3rd-party listing
99.63 %
Apr 2026
Freedom Diagnostics Moderate

For

BPC-157/Thymosin Beta-4

by Orbitrex Peptides· batch WOLV20526US

Aggregated · 3rd-party listing
99.00 %
Apr 2026
Ethos Analytics Strong · HPLC

For

BPC-157 + TB-500

by OROS Research· batch OR-LPBPCTB20-326-B4

Aggregated · 3rd-party listing
99.20 %
Apr 2026
Freedom Diagnostics Moderate · HPLC

For

BPC-157/Thymosin Beta-4

by Blank Peptides· batch 665394

Aggregated · 3rd-party listing
99.78 %
Apr 2026
Biogenica Labs

For

BPC-157/TB-500 (Wolverine)

by Amino Club· batch WLV0002

Aggregated · 3rd-party listing
99.61 %
Apr 2026
Biogenica Labs

For

BPC-157/TB-500 (Wolverine)

by Amino Club· batch WLV0001

Aggregated · 3rd-party listing
99.18 %
Apr 2026
Freedom Diagnostics Moderate · HPLC

For

BPC-157 + TB-500

by Peptide Supply Co.· batch BPTB2003312026

Aggregated · 3rd-party listing
99.80 %
Mar 2026
Vanguard Laboratory Strong

For

TB-4/BPC-157

by Orbitrex Peptides· batch WOLV200226

Aggregated · 3rd-party listing
99.54 %
Mar 2026
Freedom Diagnostics Moderate

For

TB-500/BPC-157

by Real Peptides· batch Black Cap

Aggregated · 3rd-party listing
99.42 %
Mar 2026
Freedom Diagnostics Moderate

For

Wolve 5mg/5mg (TB-500 + BPC-157)

by Real Peptides· batch Black Cup

Aggregated · 3rd-party listing
99.85 %
Mar 2026
Kovera Labs · HPLC

For

BPC-157 + TB-500

by Glacier Aminos· batch BPTB20GA-03

Aggregated · 3rd-party listing
99.94 %
Mar 2026
Kovera Labs · HPLC

For

BPC-157 + TB-500

by Mile High Compounds· batch WLV-020-MH-02

Aggregated · 3rd-party listing
99.52 %
Feb 2026
Freedom Diagnostics Moderate

For

BPC-157/Thymosin Beta-4

by Ion Peptide· batch BB10-02032026

Aggregated · 3rd-party listing
99.12 %
Jan 2026
Freedom Diagnostics Moderate · HPLC

For

BPC-157/Thymosin Beta-4

by Glacier Aminos· batch BPTB20GA-02

Aggregated · 3rd-party listing
98.86 %
Jan 2026
Freedom Diagnostics Moderate · HPLC

For

BPC-157/Thymosin Beta-4

by Glacier Aminos· batch BPTB10GA-03

Aggregated · 3rd-party listing
99.24 %
Dec 2025
Freedom Diagnostics Moderate · HPLC

For

BPC-157/Thymosin Beta-4

by Glacier Aminos· batch BPTB20GA01

Aggregated · 3rd-party listing
99.22 %
Dec 2025
Freedom Diagnostics Moderate · HPLC

For

BPC-157/Thymosin Beta-4

by Simple Peptide· batch BPCTB11192025-J

Aggregated · 3rd-party listing
99.62 %
Dec 2025
Chromate Moderate

For

Wolverine 2.0 30mg

by Mile High Compounds· batch WL2-030-MH-01

Aggregated · 3rd-party listing
99.01 %
Nov 2025
Freedom Diagnostics Moderate · HPLC

For

BPC-157/Thymosin Beta-4

by Simple Peptide· batch BPTB11192025-J

Aggregated · 3rd-party listing
99.23 %
Oct 2025
Freedom Diagnostics Moderate · HPLC

For

BPC-157/TB4

by Simple Peptide· batch BPCTB410242025-04

Research depth

6 citations indexed for BPC-157 + TB-500

All research on BPC-157 + TB-500 →

Study · 2026

Peptide Supplements and Their Therapeutic Applications in Sports Medicine

Background The peptide supplement market has experienced rapid growth due to marketing claims of enhanced performance and accelerated recovery from musculoskeletal injury.

Study · 2026

Paper 32. Performance & Promises: A Social Media Review of Alleged Indications, Risks and Usage of “Peptides” in Musculoskeletal Health

animal · 2026

Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study

Objectives This study aims to evaluate the effects of BPC-157, synthetic thymosin beta-4 (TB-500), and their combination on Achilles tendon healing using biomechanical, histopathological, histochemical, and immunohistochemical analyses in a rat model.

review · 2026

Therapeutic peptides in gerontology: mechanisms and applications for healthy aging

Background Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline.

review · 2026

Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks

Unregulated peptide use is emerging as a digitally mediated public health concern.

review · 2026

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions

Therapeutic peptides are emerging as promising adjuncts in the management of orthopaedic injuries, grounded in their ability to modulate molecular signaling networks central to cellular medicine.